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Abstract
Background: While the H1N1v influenza pandemic in 2009 was clinically mild, with a low case-fatality rate, the overall
disease burden measured in quality-adjusted life years (QALY) lost has not been estimated. Such a measure would allow
comparison with other diseases and assessment of the cost-effectiveness of pandemic control measures.
Methods and Findings: Cases of H1N1v confirmed by polymerase chain reaction (PCR) and PCR negative cases with similar
influenza-like illness (ILI controls) in 7 regions of England were sent two questionnaires, one within a week of symptom
onset and one two weeks later, requesting information on duration of illness, work loss and antiviral use together with EQ-
5D questionnaires. Results were compared with those for seasonal influenza from a systematic literature review. A total
QALY loss for the 2009 pandemic in England was calculated based on the estimated total clinical cases and reported deaths.
A total of 655 questionnaires were sent and 296 (45%) returned. Symptoms and average illness duration were similar
between confirmed cases and ILI controls (8.8 days and 8.7 days respectively). Days off work were greater for cases than ILI
controls (7.3 and 4.9 days respectively, p=0.003). The quality-adjusted life days lost was 2.92 for confirmed cases and 2.74
for ILI controls, with a reduction in QALY loss after prompt use of antivirals in confirmed cases. The overall QALY loss in the
pandemic was estimated at 28,126 QALYs (22,267 discounted) of which 40% was due to deaths (24% with discounting).
Conclusion: Given the global public health significance of influenza, it is remarkable that no previous prospective study of
the QALY loss of influenza using standardised and well validated methods has been performed. Although the QALY loss was
minor for individual patients, the estimated total burden of influenza over the pandemic was substantial when compared to
other infectious diseases.
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Introduction
Influenza severity is usually characterised by the case-fatality
rate (CFR). There are major problems with this measure as the
denominator (the number of cases) is difficult to ascertain, resulting
in widely varying estimates for the same viral strain [1]. Using the
CFR to characterise severity ignores the burden of disease in the
vast majority of individuals who have symptomatic influenza
(possibly severe) but do not die. Many millions of individuals were
infected with the pandemic strain of influenza A/H1N1v in 2009,
and it is likely that many more will be infected by related strains in
the coming years. In order to help evaluate the overall impact of
the 2009 H1N1v pandemic on the health of populations it is
necessary to measure the burden associated with non-fatal as well
as fatal cases. One simple way to measure the impact would be to
use a measure that combines morbidity and mortality in a single
unit. Quality Adjusted Life Years (QALYs) are a commonly used
metric that has this property. The EQ-5D is a generic preference-
based instrument designed to measure the health related quality of
life (QoL or QALY-weight) of any disease state. Using this
instrument allows quantification of the severity of H1N1v on a
comparable and standardised scale. It enables rational decisions to
be made about interventions in future waves of H1N1v by
comparing, for instance, the cost per QALY gained from such
interventions with nationally accepted norms. In addition, it gives
more in depth understanding of the impact of influenza on
different aspects of well being.
The health-related quality of life detriment from a population-
based sample of confirmed H1N1v patients was prospectively
measured and compared to controls who were investigated
because they had influenza like illness (ILI), but were not
laboratory confirmed as H1N1v. The aims were: 1) to quantify
the burden of H1N1v for individual patients and investigate
factors, such as age and treatment with antivirals, that may affect
this; 2) compare the severity of the 2009 strain to other infections
that cause ILI and previous estimates of the severity of influenza
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burden attributed to H1N1v in the population. The findings can
then be used to inform effectiveness and cost-effectiveness analyses
on policy decisions related to the control of future waves of this or
related viruses.
Methods
Prospective study of severity of H1N1v
The EQ-5D is a combination of a questionnaire and a valuation
technique. The tool values health-related quality of life in five
dimensions: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. For each dimension there are three levels:
no problems, some problems and severe problems. The overall
health status is also measured using the visual analogue scale
(VAS). The power of the EQ-5D is that it makes it possible to
convert an outcome for each dimension of this scale into a quality
of life score. It is recommended by the National Institute for
Clinical Excellence for use in cost-effectiveness analyses in the UK
[2]. During the early stages of the 2009 pandemic PCR confirmed
cases of influenza A/H1N1v and a control group of PCR negative
cases of ILI were identified. The PCR test used was validated and
has a good specificity and a sensitivity of 95.4% [3]. During this
time (weeks 27/28 2009) the containment phase of the response to
the pandemic was still in place in England and all cases of
influenza were being actively traced and centrally registered on a
single database (Fluzone), irrespective of risk status, age group,
complications, etc. Demographic, clinical, and epidemiological
information was recorded on each case, including name, age,
address, date of onset, and whether the case had been confirmed
as H1N1v, tested and confirmed as not being H1N1v (discarded),
or was awaiting test confirmation. The database was updated
daily. Cases found to be negative for H1N1v (ILI controls) were
not investigated further, and so their aetiology is unknown. From
this database, patients who had confirmed H1N1v and those who
had ILI but had tested negative for H1N1v, who had a date of
onset within 1 week of the (then) current date were contacted by
post and asked to take part in the survey. During the period of the
study, two regions of England (London and the West Midlands)
stopped investigating every case. To avoid biasing the results of the
survey, we excluded cases from these regions.
The Fluzone database was checked daily during the recruitment
period (weeks 27 and 28 2009) for new cases of ILI with recent
onset (i.e. onset within 1 week of the day on which the database
was checked) who were not resident in London or West Midlands.
These were then contacted and asked to participate. The covering
letter explained the study and contained instructions for
completing the survey. The questionnaire asked for age, sex,
presence of pre-disposing conditions (diabetes, asthma or other
chronic respiratory diseases, chronic heart, kidney or liver disease,
long-term neurological disease, or immuno-suppression), atten-
dance at hospital, date of onset of symptoms, whether antivirals
were being taken, and if so when they were first taken, and a
checklist documenting their symptoms on the day of the survey
and on their worst day of illness. In addition, they were asked to fill
in the two copies of the EQ-5D, one for the worst day of their
illness and one for the day they filled in the questionnaire. A
second questionnaire was sent out two weeks after the first, which
requested information on the total duration of symptoms, and
absenteeism from work or school. Respondents were also asked to
fill in another EQ-5D questionnaire on that day to obtain a
baseline score for their health-related quality of life. In case there
was no response from the first mailing a reminder was sent out,
containing both questionnaires. Non-responders to the second
questionnaire were not followed up. Patients could fill in the
questionnaires by post or on-line (they were provided with a secure
login to enable this).
Children (,16 years) were sent a child version of the EQ-5D [4]
and questions were altered somewhat (e.g. absence from school
instead of work). A separate question on the work loss of the
parents due to disease in the child was added. In the covering letter
(addressed to the guardian) it was suggested that older children fill
in the survey themselves (with the assistance of the parent/
guardian) and that for younger ones the parent/guardian fill out
the survey on their behalf. Copies of the questionnaires and cover
letters are available from the authors on request.
Enquiry to the NHS Research Ethics Committee indicated that
ethics approval for this study was not required, since collection of
QoL information from patients is part of the routine surveillance
activities of the Health Protection Agency (HPA).
Only individuals with an ILI should have been investigated for
H1N1v but to be certain, we asked respondents whether they had
fever plus at least one other respiratory symptom on their worst
day of illness. In the statistical analysis, only cases and control
participants who recorded that they had symptoms consistent with
an ILI were included. Differences between the two groups
(confirmed cases and ILI controls) were tested having corrected
for multiple comparisons using the S ˇida ´k correction (an exact
version of the Bonferroni correction). For the QALY analysis, we
only included patients for whom a complete set of data was
available to calculate the QALY loss; this is an onset and end date,
as well as quality of life weights for the worst day and the date of
onset. The overall QALY loss was estimated to be the area
denoted by the triangle with vertices being the background quality
of life weight at onset date, the quality of life weight at the worst
day and the time since onset of the worst day, and the background
quality of life weight at the recovery date. Attribution of risk
factors to the QALY score was investigated by linear regression. In
the regression QALY scores were logged to take account of the
skew in the original data. Statistical analysis was performed with R
version 2.11.0.
Systematic literature review
To compare our results with previous estimates of the quality of
life detriment due to influenza we performed a literature review.
PubMed was searched for the terms ‘influenza’ and ‘quality-
adjusted life year’, ‘QALY’, ‘QALD’ or ‘EQ-5D’. The abstracts of
all identified papers were reviewed, and original articles (not
reviews) published in English were retained.
Overall disease burden
To estimate the overall disease burden in England for the 2009
H1N1v pandemic, we focussed on the number of cases presenting
with fever and those who died. The estimated number of people
presenting with ILI (fever+respiratory symptom) was based on the
estimated number of infections. To obtain the latter the estimated
total number of clinical cases [5] in the first and second waves in
England was multiplied by a factor 10. This factor is based on a
comparison of the estimated clinical cases and seroprevalence after
the first wave in England [6]. Although it might be justified to use
a higher multiplication factor for the second wave based on
mortality and other surveillance data [5,7], the same multiplier
was used for the whole period and can therefore be seen as a
conservative approach. To obtain the estimated number of
infected persons presenting with ILI, the number of infections
was multiplied by the proportion of infections presenting with
fever (27%) as estimated from an intensive household follow up
during the initial stages of the 2009 pandemic [8]. The total
Impact of Influenza H1N1 on the Quality of Life
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loss obtained in this study by the number of infections presenting
with ILI, plus the QALY loss for fatal cases. The QALY loss for
fatal cases was estimated as the average life-expectancy corrected
for the expected quality of life in those years [9]. This assumes that
each recorded death was actually caused by H1N1v, that there
was no under-reporting of deaths, and that despite most deaths
being in risk groups, the average life-expectancy was lost per
death. The baseline estimate assumed no discounting of future life-
expectancy. Discounting at 3.5% [2] was also used in the
sensitivity analysis.
Results
Prospective study of severity of H1N1v
A total of 655 patients met the inclusion criteria and were sent a
questionnaire, of whom 390 were confirmed cases and 265 were
ILI controls. We received 287 responses, of which 269 reported
ILI and were included in the analysis, 186 from confirmed cases
and 83 from ILI controls. The response rate was significantly
higher in the confirmed H1N1v group (48% vs 31% p,0.001).
This difference was slightly larger in children (55% vs 31%).
The demographic composition of the two groups was similar
(Table 1). Although there was a slightly higher fraction of the
control group that was in a risk group (25% vs 19%) this was not
significant. The hospitalisation rate was 8–9% in both groups. This
high level of hospitalisation may represent heightened concern at
the outset of the epidemic. Antiviral use was higher among the
confirmed cases (although this was not significant after adjusting
for multiple comparisons). The proportion of cases receiving
antivirals within 2 days of onset was similar between the two
groups.
The symptoms recorded by both groups were similar (Table 2).
The only significant difference was that the confirmed H1N1v
cases recorded more occurrences of cough (90% vs 64%,
p,0.001). The duration of symptoms was not known for
everybody due to non-respondents to the second questionnaire.
Nevertheless, the duration was similar for the two groups (average
duration of 8.8 and 8.7 days respectively for the confirmed and
control group). The duration of time off work was 7.3 days for the
confirmed cases and 4.9 for the ILI controls: a significant
difference using the Welch two sided t-test (p=0.003). The worst
day of disease appeared shortly after onset of the symptoms for
both groups, however for the control group the worst day was
slightly later (median 2 days) after onset than for the confirmed
cases (median 1 day after onset) (Table 2).
All five of the dimensions measured in the EQ-5D were affected
by ILI, in both groups of patients, though usual activities and
pain/discomfort were the most affected (Table 3). Only about 5%
of patients said that they had no problems with pain or discomfort
on the worst day of illness, and 2% (8%) said they had no problems
with usual activities on the worst day of their illness in the
confirmed (control) groups.
The overall quality of life weight for the worst day was 0.29 for
the confirmed cases and 0.34 for the ILI controls (Table 4). After
the symptoms had gone the quality of life weights were 0.96 and
0.97 respectively. Based on the VAS scale the QALY weight was
90 (on scale 0–100) for the background and 30 for the worst day.
The comparable values for the ILI controls were similar, 89 and
30 respectively. Complete information to calculate an overall
QALY loss was only available for 114 of the 186 (61%) confirmed
cases and 46 (55%) of the 83 control ILI cases. The final QALY
loss due to the whole period of disease was 0.008 for the confirmed
cases and 0.0075 for the cases in the control group, i.e. 2.9 and 2.7
Quality Adjusted Life Days (QALDs), respectively.
In the multivariable linear regression only antiviral use (within
48 hours) was associated with the number of QALDs lost, and
only in confirmed H1N1v cases (p=0.084). Prompt antiviral use
was found to reduce the number of QALDs lost by 50% (22%–
110% CI 95%). No other factor (including age, sex, presence of
risk-factors, whether hospitalised, whether the case was confirmed
H1N1v or not) was significantly associated with the number of
QALDs lost.
Systematic literature review
Sixty-one articles were found, 10 of which were reviews and
discarded. A further 10 studies only estimated life years lost, two
papers described different diseases, a further two were not
published in English, leaving 36 studies mentioning the burden
of influenza or ILI. However, none of the reviewed papers was
specifically dedicated to the burden of disease, but gave values for
this as part of a cost-effectiveness study. A number of papers
Table 1. Background characteristic of patients.
Confirmed
H1N1v ILI cases
ILI controls
(non-H1N1v cases)
IlI (fever+1 other symptom) 186 (96%) 83 (89%)
Of those with ILI
Adults 115 (62%) 58 (70%)
Children 71 (38%) 25 (30%)
Risk group 36 (19%) 21 (25%)
Hospital admission 16 (9%) 7 (8%)
Antivirals 132 (71%) 44 (53%) p=0.0065*
Antivirals within 2 days after onset 65 (35%) 26 (31%)
*not significant when corrected for multiple comparisons.
doi:10.1371/journal.pone.0017030.t001
Table 2. Symptoms reported by patients.
Symptoms
Confirmed
H1N1v ILI cases
ILI controls
(non- H1N1v cases)
Sore throat 152 (82%) 68 (82%)
Cough 167 (90%) 53 (64%) p.0.001
Headache 160 (86%) 69 (83%)
Tiredness 176 (95%) 77 (93%)
Chills 142 (76%) 49 (59%) p=0.006*
Loss of appetite 147 (79%) 62 (75%)
Muscle pain 128 (69%) 54 (65%)
Joint pain 99 (53%) 51 (61%)
Nausea 87 (47%) 38 (46%)
Diarrhoea 46 (25%) 28 (34%)
Conjunctivitis 53 (28%) 18 (22%)
Average duration of symptoms
(min-max)
8.8 (1–28) n=133 8.7 (2–32) n=56
Worst day (median, mean, modus) 1, 1.64, day 1 2, 2.18, day 1
Time off work information available 82 (44%) 39 (47%)
Average time off work (min-max) 7.3 (1–28) 4.9 (1–21) p=0.003
*not significant when corrected for multiple comparisons.
doi:10.1371/journal.pone.0017030.t002
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zanamivir but with different analyses. Overall, we were only able
to identify four original sources of information on the burden of
disease due to ILI as measured in QALYs, including the trial data
as one source, see table 5 for an overview.
The first original source of data is a study by Griffin et al. [10] in
which 21 working adults were asked to fill an EQ-5D
questionnaire within 3 months of onset of ILI, and 8 GPs were
asked to do the same. The study reported relatively low QALY
weights for ILI with values below zero (corresponding to a state
worse than death) being recorded. The weights were, however,
applied to a very short duration of illness which was measured
separately on a different group of patients (2.48 days). Hence the
overall loss was estimated at 2.19 QALDs. The second source of
data is the clinical trials of zanamivir, reported by O’Brien et al.
[11] In the zanamivir trials almost 640 patients with ILI were
asked within 48 hrs of onset of disease to value their health on a
scale between 0 and 10 every day for 21 days. Since this is not a
QALY scale, several separate analyses have been performed on
the same data to map the disease-specific scale onto a QALY scale.
In addition, since these data have mostly been used in cost-
effectiveness studies of the use of antivirals, no figures for overall
QALY loss due to ILI have been published, only the difference in
QALY loss due to ILI in patients with and without antivirals
[11–14]. Only two studies [15,16] use these data to estimate the
overall QALY loss: the first uses a separate estimation of the
background quality of life weight based on population estimates
and the second a separate estimation of the duration of illness. The
final estimates differ by up to 6-fold. The QALD lost estimated by
Siddiqui et al. [16] is 1.68 for complicated influenza and 1.57 for
non-complicated, non-influenza ILI whereas the QALD loss
calculated by Sander et al. [15] is 5.33 for 0–19 yrs, 6.35 for
20–64 yrs and 10.69 in over 65 s. A third potential source of
QALY loss data is a study in which 15 randomly selected working
age patients and health care workers [17] were asked to fill in the
HUI-3 questionnaire based on their recollection of their most
recent episode of ILI. The results were used to estimate a quality of
life weight of 0.25 for an individual with ILI. Unfortunately, the
duration that someone is in this state was not determined and so
no QALY loss due to an episode of ILI can be easily calculated
from these data. The fourth source of data is a study by Prosser et
al. [18] in which parents were asked how much time they were
willing to trade off their own life to prevent ILI in their children,
which resulted in a value of 1.825 QALDs lost per ILI case.
Total burden of disease pandemic
Given the estimated QALY loss in this study the overall burden
of the 2009 H1N1v pandemic in England was around 28,126
QALYs (22,267 discounted). This is because almost a 7.8 million
people were estimated to be infected with the novel virus over the
course of the two waves of disease. Of these, around 2.1 million
were estimated to have experienced fever and there were 337
Table 3. Impact on the 5 dimensions as measured in the EQ-5D.
No problems Some problems Severe problems
H1N1v ILI controls H1N1v ILI controls H1N1v ILI controls
Background
Self care 125 (98%) 51 (96%) 1 (1%) 2 (4%) 1 (1%) 0 (0%)
Mobility 122 (96%) 52 (98%) 4 (3%) 1 (2%) 1 (1%) 0 (0%)
Usual activities 115 (90%) 50(94%) 11(9%) 3 (6%) 1 (1%) 0 (0%)
Pain/discomfort 118 (93%) 50(94%) 8 (6%) 3 (6%) 1 (1%) 0 (0%)
Anxiety/Depression 123 (97%) 50(94%) 4 (3%) 3 (6%) 0 (0%) 0 (0%)
Worst day
Self care 83 (46%) 38 (48%) 57 (31%) 28(35%) 41(23%) 13(16%)
Mobility 31(17%) 17 (20%) 72 (39%) 34 (41%) 81 (44%) 32 (39%)
Usual activities 3 (2%) 7 (8%) 53 (29%) 25 (30%) 126 (69%) 51 (61%)
Pain/discomfort 8 (4%) 4 (5%) 111 (60%) 48 (59%) 65 (35%) 30 (37%)
Anxiety/Depression 82 (45%) 30(37%) 57 (31%) 37 (46%) 43 (24%) 14 (17%)
doi:10.1371/journal.pone.0017030.t003
Table 4. Impact of ILI on health related quality of life for H1N1v confirmed and non-H1N1v ILI control patients.
Confirmed H1N1v ILI cases ILI controls (non-H1N1v cases)
EQ-5D Background (min-max,median) 0.96 (0.15–1,1) 0.97 (0.5–1,1)
EQ-5D Worst day (min-max,median) 0.29 (20.073–1,0.24) 0.34 (20.073–1,0.24)
VAS Background (min-max,median) 90 (20–100,95) 89 (55–100, 90)
VAS Worst day (min-max,median) 30 (0–100,25) 30 (5–80,30)
Overall QALY loss (min-max,median) 0.008 (0–0.027,0.006) 0.0075 (0–0.044,0.006)
Overall QALD loss (min-max,median) 2.92 (0–9.84, 2.18) 2.74 (0–16.2, 2.12)
doi:10.1371/journal.pone.0017030.t004
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the QALY loss attributable to H1N1v.
Discussion
Given the global public health significance of influenza, it is
remarkable how few studies have tried to quantify the morbidity
and mortality impact in QALYs of this ubiquitous disease. In
addition, as our systematic review reveals, the studies that have
been performed often have considerable methodological limita-
tions. For instance, two of the studies were small and retrospective
[10,17], two studies collected data from proxies (such as GPs) in
addition to or instead of patients [10,19], and the studies based on
the zanamivir trial did not use standardised instrument and only
estimated the difference in QALYs lost when on antivirals [11].
Finally, many of the studies did not estimate the duration of illness,
and no previous study explicitly mentions their assumptions about
the shape of the QALY loss (e.g. rectangular or triangular). This
study is the only prospective population-based study of the health-
relative quality of life impact of confirmed influenza and influenza-
like illness that uses a standardised and well-validated instrument
(the EQ-5D). The study shows that the overall QALY loss for
confirmed H1N1v and other non-H1N1v influenza-like-illness was
similar, at around 2.8 QALDs per patient. The study also
confirmed that the range of symptoms and the severity of illness
appeared similar in the two groups of patients, with the vast
majority of patients reporting some problems with usual activities
and pain and discomfort when they were ill with influenza or ILI.
Only the prompt use of antivirals was significantly associated with
a reduction in the QALDs lost, and only in the confirmed cases.
Although deaths from H1N1v were comparatively rare, our study
suggests that the overall burden of illness was considerable with
more than 28,000 QALYs lost over the two waves of infection in
England. This compares with an estimated QALY loss per year of
18,000 for chickenpox and shingles combined [20] and 97,000 for
type 1 diabetes [21]. However compared to a high mortality
disease such as coronary heart disease which has an estimated
annual burden of 8.2 million QALYs lost [21], it is relatively small.
The main strength of the study was that it was a population-
based prospective controlled study. The study was carried out
during a period when every case seeking health care actively was
investigated, with follow-up of all confirmed cases and their
contacts. Therefore, it should be as representative a study is likely
to be possible. Indeed, during the period of the study the two
regions that were most heavily affected at the beginning of the
epidemic (London and the West Midlands) stopped investigating
every possible case, and so we excluded data from these regions to
prevent bias. Nevertheless the possibility remains that more severe
cases were more likely to come to the attention of medical
authorities. In addition, although the overall response rate was
good for a postal survey (.40%), there is always the possibility that
more severely affected patients were more likely to return the
questionnaire. Most patients probably knew their status (i.e.
whether they were a confirmed H1N1v case or not), which may
have led to the differential response between confirmed and other
ILI cases. Hence, although every effort was made to reduce bias,
there remains the possibility that the average loss estimated here is
an overestimate of the true QALY loss per case.
The total burden of influenza in the population is probably
underestimated, however, as we do not include the QALY loss
Table 5. Overview of different published estimates of QALDs lost due to ILI, for sources which presented data or interpretation of
that data.
Study
QALY weight
Worst day/disease
Background
QALY weight
Duration of
disease (days) QALD loss Sample size Method Focus group Age group
(Griffin, Perry, &
Fleming, 2001)
20.066 0.817 2.48 2.19* 21 EQ-5D Patients (within
3 months
after onset)
18+
(Griffin, Perry, &
Fleming, 2001)
20.263 0.72 2.48 2.45* 8 EQ-5D GPs Unknown
(O’Brien, Goeree,
Blackhouse, Smieja,
& Loeb, 2003)
Changed by day Not reported Not reported Not reported 920 in placebo
(639 with
influenza
Likert score
transferred to
VAS
ILI patients
(clinical trails
antivirals GSK)
18–64
(Turner et al.,
2003)
Changed by day Not reported Not reported Not reported See O’Brien
at al
Converted the
Likert scores into
VAS scores
converted those into
time-trade off scores
ILI patients
(clinical trails
antivirals GSK)
18–64
(Rothberg,
Bellantonio,
& Rose, 2003)
0.25 1 Not reported Not reported 15 HUI-3 Patients Working
adults
(Prosser et al.,
2006)
Not reported Not reported Not reported 1.83 Not reported Time trade off Parents of
children
Children
(Siddiqui &
Edmunds,
2008)
VAS scores as
presented by
O’Brien et.al
0.85 Not reported 1.68 for
influenza ILI
1.57 for non-
influenza ILI
See O’Brien
et.al.
VAS scores
substracted from
the baseline
ILI patients 18–64
(Sander et al.,
2010)
QALY scores as
presented by
Turner et.al.
Not reported Not reported 5.33 (0–19 yrs)
6.35 (20–64 yrs)
10.69 (65+)
See O’Brien
et.al
Uses published
QALY weights and
combines this
with unpublished
disease duration
ILI patients 18–64
doi:10.1371/journal.pone.0017030.t005
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were investigated and their data recorded on the Fluzone
database. Thus patients with milder symptoms – particularly
those lacking fever – were not followed up. Carat et al. [22] suggest
that about one half of influenza patients with respiratory
symptoms do not develop fever. These individuals probably have
a lower QALY loss than febrile cases. Indeed, of the 18 individuals
who reported not having fever, 7 responded to both question-
naires, with an average loss of 1.2 QALDs per case. Little weight
should be put on these numbers as the study was not designed to
ascertain the burden of non-febrile acute respiratory illness, and
the sample is small. However, as there may have been large
numbers of patients without fever their contribution to the overall
burden may have been significant. A preliminary literature review
for QALY loss for acute respiratory illness revealed no papers, and
so this remains an area for further study.
Our findings suggest that prompt use of antivirals reduces the
number of QALDs lost. There are (to our knowledge) no other
data on the effect of antivirals on health related quality of life of
H1N1v patients. Our findings confirm the results from clinical
trials on seasonal influenza [11], and are also in accordance with
virological data, which seem to suggest that antivirals reduce viral
load in H1N1v infected patients [23]. Other factors, such as age,
were not significantly associated with severity as measured by
QALDs lost, which also seemed to confirm the findings of
virological studies of H1N1v [23].
This study provides important baseline information on the
severity of H1N1v and other influenza-like-illnesses that can be
used to judge the overall impact of these diseases on the health of
populations. This will facilitate rational decision-making regarding
the control of influenza over the coming seasons.
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